Tradestie Institutional Equity Comparison Engine

BCAX vs NRIX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NRIX Overall Edge

NRIX Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nurix Therapeutics, Inc. Common stock (NRIX) driven by superior Valuation, Growth & Margin, Momentum & Technical while BCAX counters with relative strength in Options & Structure. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NRIX at N/M Forward P/E and 41.3% operating margin (+8426.3% YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against NRIX sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner NRIX
BCAX N/M vs NRIX N/M Fwd P/E
Growth & Margin Winner NRIX
Op Margin 0.0% vs 41.3% ยท YoY +0.0% vs +8426.3%
Momentum & Technical Winner NRIX
1Y -31.6% vs +18.5% ยท 52W Pos 8% vs 17%
Options & Structure Winner BCAX
BREAKDOWN (23rd %ile IV) vs BREAKDOWN (4th %ile IV)
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $665.2M
1M Return -41.9%
1Y Return -31.63%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
NRIX NASDAQ
Nurix Therapeutics, Inc. Common stock
Pharmaceutical Preparations
$14.73
-4.84% 1D
Market Cap $1.7B
1M Return -39.68%
1Y Return +18.5%
Forward P/E N/M
Unified AI Score
52.9 / 100 HOLD
Tech 55.0 Fund 58.0 Flow 64.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BCAX -31.63% NRIX +18.5% Spread: +50.13 pp (NRIX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BCAX TTM Op. Margin: 0.0% NRIX TTM Op. Margin: 41.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs NRIX. Trailing 12-month operating profitability (BCAX 0.0% vs NRIX 41.3%) and valuation multiples (BCAX N/M vs NRIX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BCAX (0) vs NRIX (9)
Institutional Metric BCAX NRIX Criterion Row Winner
Market Capitalization Scale $665.2M $1.7B Larger Scale NRIX
Trailing P/E Ratio Valuation N/M 6.4x Lower Multiple NRIX
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +8426.3% Higher Growth NRIX
Operating Margin (TTM) Profitability 0.0% 41.3% Higher Margin NRIX
Net Profit Margin Profitability 0.0% 42.0% Higher Margin NRIX
Return on Equity (ROE) Capital Efficiency -54.2% 44.0% Higher ROE NRIX
52-Week Range Position Momentum 8% ($8โ€“$31) 17% ($12โ€“$28) Stronger Trend NRIX
Beta / 30D Volatility Risk Regime 1.42ฮฒ ยท 184% Vol 0.95ฮฒ ยท 141% Vol Lower Realized Risk NRIX
Unified Institutional Score Composite Signal 52.1 / 100 (HOLD) 52.9 / 100 (HOLD) Higher Composite NRIX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BCAX vs NRIX Buy Guide
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NRIX BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live NRIX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BCAX nor NRIX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.